Fig. 4From: Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trialsSubgroup analysis of denosumab versus ZA in solid tumors. Forest plots of time to first SRE (A), time to first-and-subsequent SREs (B), overall survival (C), and time to disease progression (D)Back to article page